*Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 million in net proceeds from the recently completed July 2025 public offering.
Related Questions
What is the expected use of the $65.1 million net proceeds from the July 2025 public offering?
How will the $203.6 million cash and marketable securities balance affect the company’s runway and valuation?
Will the recent public offering lead to significant dilution for existing shareholders?
How does Larimar’s current cash position compare to its peers in the biotech sector?
What milestones or catalyst events is the company targeting with this capital in the next 12‑18 months?
How might the increased liquidity influence the stock’s short‑term price momentum?
What are the potential risks if the company fails to meet its projected cash‑burn rate?
Will the market re‑price the stock based on the improved balance sheet and reduced financing risk?
How does this capital raise impact the company’s long‑term strategic plan and partnership opportunities?
Is the cash balance sufficient to fund upcoming clinical trial expenses without additional financing?